Magi3 Antibody

What is MAGI3 and what are its primary functions?

MAGI3 (Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3) is a scaffolding protein located at cell-cell junctions that regulates various cellular and signaling processes. It cooperates with PTEN to modulate the kinase activity of AKT1 and interacts with receptor tyrosine phosphatases. In polarized epithelial cells, MAGI3 is involved in efficient trafficking of TGFA to the cell surface. It also regulates the ability of LPAR2 to activate ERK and RhoA pathways and regulates the JNK signaling cascade via its interaction with FZD4 and VANGL2 . The protein is widely expressed and colocalizes with TGFA in neurons in the cortex and dentate gyrus, as well as in ependymal cells and some astrocytes .

What is the molecular structure and weight of MAGI3?

MAGI3 is a 130 kDa guanylate kinase that belongs to a family of multi-PDZ domain containing guanylate kinases. The mouse variant has a molecular mass of approximately 161.672 kDa. The protein structure consists of an N-terminal guanylate kinase domain, followed by a WW domain (named for two conserved tryptophan residues), and five PDZ domains . This complex domain structure allows MAGI3 to interact with multiple protein partners and participate in various signaling pathways.

How do I choose the appropriate MAGI3 antibody for my specific application?

When selecting a MAGI3 antibody, consider these key factors:

• Application compatibility: Determine whether the antibody has been validated for your specific application (WB, IF, IHC, ELISA, etc.)

• Species reactivity: Ensure the antibody recognizes MAGI3 in your species of interest (human, mouse, etc.)

• Specificity: Review validation data showing the antibody recognizes MAGI3 without cross-reactivity

• Clonality: Choose between polyclonal (broader epitope recognition) or monoclonal (single epitope specificity) based on your needs

• Host species: Select an antibody raised in a species that won't cause cross-reactivity issues with your experimental system

For example, if studying human samples with western blotting, select an antibody like ABIN6243878 which has been validated for human MAGI3 in WB applications .

What validation methods should I use to confirm MAGI3 antibody specificity?

To confirm MAGI3 antibody specificity, implement a comprehensive validation strategy:

• Positive and negative controls: Test on tissues/cells known to express or lack MAGI3

• Molecular weight verification: Confirm the detected band matches MAGI3's expected molecular weight (130-160 kDa)

• Knockdown/knockout validation: Compare signals between MAGI3 knockdown/knockout and wild-type samples

• Peptide competition: Pre-incubate the antibody with the immunizing peptide to block specific binding

• Orthogonal detection: Compare results with a second antibody targeting a different MAGI3 epitope

Reputable vendors validate their antibodies by testing them on tissues known to express MAGI3 positively and negatively , but independent validation in your specific experimental system is still recommended.

What are the optimal protocols for using MAGI3 antibodies in western blotting?

For optimal western blotting with MAGI3 antibodies:

• Sample preparation:

  • Use RIPA buffer with protease inhibitors

  • Include phosphatase inhibitors if studying MAGI3 phosphorylation status

  • Heat samples at 95°C for 5 minutes in Laemmli buffer

• Gel electrophoresis:

  • Use 8-10% SDS-PAGE gels due to MAGI3's large size (130-160 kDa)

  • Run alongside molecular weight markers that span 100-170 kDa range

• Transfer:

  • Use wet transfer for large proteins (overnight at 30V, 4°C)

  • Transfer to PVDF membrane (preferred over nitrocellulose for large proteins)

• Antibody incubation:

  • Block with 5% non-fat milk in TBST for 1 hour at room temperature

  • Incubate with primary MAGI3 antibody at recommended dilution (typically 1:500-1:1000)

  • Use overnight incubation at 4°C for optimal results

  • Wash extensively (4 × 10 minutes) with TBST

  • Incubate with appropriate HRP-conjugated secondary antibody

• Detection:

  • Use enhanced chemiluminescence and expose to film or digital imager

  • Expected band: 130-160 kDa for full-length MAGI3

Note: Some studies have identified truncated forms of MAGI3 resulting from premature polyadenylation events, which may appear as additional lower molecular weight bands .

How can I optimize immunohistochemistry protocols with MAGI3 antibodies?

For optimal immunohistochemistry results with MAGI3 antibodies:

• Tissue preparation:

  • Use freshly fixed tissues (10% neutral buffered formalin for 24-48 hours)

  • Paraffin embedding with standard protocols

  • Section at 4-5 μm thickness

• Antigen retrieval (critical step):

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Pressure cooker method (20 minutes) provides consistent results

• Blocking and antibody incubation:

  • Block endogenous peroxidase (3% H₂O₂, 10 minutes)

  • Block non-specific binding (5% normal serum from secondary antibody host species)

  • Incubate with MAGI3 antibody at 1:100 dilution overnight at 4°C

• Detection:

  • Use appropriate detection system (e.g., HRP-polymer)

  • Develop with DAB substrate

  • Counterstain with hematoxylin

• Interpretation:

  • Look for membrane and nuclear staining patterns, as observed in human fetal testis tissue

  • Include positive controls (tissues known to express MAGI3)

This protocol has been successful with antibodies like ab118615, which shows membrane and nuclear staining in human tissues .

How can I use MAGI3 antibodies for co-immunoprecipitation to study protein-protein interactions?

For effective co-immunoprecipitation (co-IP) of MAGI3 and its binding partners:

• Sample preparation:

  • Use mild lysis buffer to preserve protein-protein interactions:

    • 50 mM Tris-HCl pH 7.5

    • 150 mM NaCl

    • 1% NP-40 or 0.5% Triton X-100

    • 1 mM EDTA

    • Protease/phosphatase inhibitors

  • Clear lysate by centrifugation (14,000 × g, 10 minutes, 4°C)

• Antibody binding:

  • Pre-clear lysate with Protein A/G beads (1 hour, 4°C)

  • Incubate cleared lysate with MAGI3 antibody (5 μg per 1 mg protein) overnight at 4°C

  • Add pre-washed Protein A/G beads and incubate 2-4 hours at 4°C

• Washing and elution:

  • Wash beads 4-5 times with cold lysis buffer

  • Elute bound proteins with 2× Laemmli buffer at 95°C for 5 minutes

• Analysis:

  • Run samples on SDS-PAGE

  • Western blot for MAGI3 and suspected interaction partners (MAS receptor, PTEN, TGFA, etc.)

This approach has been useful for studying the interaction between MAGI3 and the MAS receptor, which mediates its role in regulating ERK signaling and sunitinib sensitivity in renal cell carcinoma .

What are the common pitfalls when using MAGI3 antibodies and how can I troubleshoot them?

When troubleshooting, always include positive controls (e.g., IMR32 or HeLa cells for human MAGI3) and consider using multiple antibodies targeting different epitopes to confirm results.

How does MAGI3 expression correlate with cancer progression, particularly in renal cell carcinoma?

MAGI3 expression shows significant correlation with cancer progression in clear cell renal cell carcinoma (ccRCC):

These findings highlight MAGI3's potential as both a prognostic biomarker and a therapeutic target in ccRCC.

How does MAGI3 expression affect sunitinib sensitivity in cancer treatment?

MAGI3 plays a critical role in modulating sensitivity to sunitinib treatment, particularly in renal cell carcinoma:

This relationship between MAGI3 expression and drug sensitivity provides a rationale for using MAGI3 as a predictive biomarker for personalized treatment approaches.

How can I design experiments to investigate MAGI3's role in signaling pathways using antibody-based techniques?

To effectively investigate MAGI3's role in signaling pathways:

• Pathway activation analysis:

  • Design stimulation experiments with agonists (e.g., Ang-(1-7) for the MAS receptor pathway)

  • Use pathway inhibitors (A779 for MAS receptor) to confirm specificity

  • Analyze phosphorylation status of downstream effectors (ERK, JNK) by western blotting

  • Include time-course experiments (5-60 minutes) to capture signaling dynamics

• Protein-protein interaction mapping:

  • Implement co-immunoprecipitation with MAGI3 antibodies followed by mass spectrometry

  • Perform proximity ligation assays to visualize MAGI3 interactions in situ

  • Use sequential co-IP to identify multiprotein complexes containing MAGI3

• Functional domain analysis:

  • Design experiments to target specific MAGI3 domains:

    • PDZ domains (protein-protein interactions)

    • WW domain (protein-protein interactions)

    • Guanylate kinase domain (enzymatic activity)

  • Use domain-specific antibodies or tagged constructs for each domain

• Subcellular localization studies:

  • Perform immunofluorescence with MAGI3 antibodies and markers for subcellular compartments

  • Use subcellular fractionation followed by western blotting

  • Analyze co-localization with signaling partners (MAS receptor, PTEN, etc.)

• Functional manipulation experiments:

  • Combine antibody-based detection with MAGI3 knockdown/overexpression

  • Monitor changes in pathway activity with phospho-specific antibodies

  • Design rescue experiments to confirm specificity of observed effects

This comprehensive approach will help establish MAGI3's specific role within complex signaling networks.

What are the considerations for using MAGI3 antibodies in flow cytometry and multiparameter analysis?

When incorporating MAGI3 antibodies into flow cytometry protocols:

• Antibody selection considerations:

  • Choose antibodies validated specifically for flow cytometry

  • Select fluorophore conjugates that fit within your panel design

  • Consider brightness requirements based on MAGI3 expression levels

  • If using unconjugated primary antibodies, ensure secondary antibody compatibility

• Sample preparation optimization:

  • For intracellular MAGI3 detection:

    • Fixation: 4% paraformaldehyde (10 minutes, room temperature)

    • Permeabilization: 0.1% Triton X-100 or commercial permeabilization buffers

    • Blocking: 5% serum from secondary antibody species (30 minutes)

  • Include viability dye to exclude dead cells, which can bind antibodies non-specifically

• Panel design for multiparameter analysis:

  • Consider spectral overlap when designing panels including MAGI3

  • Include markers for relevant cell populations and signaling events

  • Use fluorescence minus one (FMO) controls to set accurate gates

  • Consider instrument configuration limitations

• Controls specific for MAGI3 analysis:

  • Biological controls: MAGI3 knockdown/knockout cells

  • Technical controls: Isotype controls, secondary-only controls

  • Compensation controls: Single-color controls for each fluorophore

• Data analysis recommendations:

  • Gate on single, viable cells before analyzing MAGI3 expression

  • Consider using fluorescent cell barcoding for comparing multiple treatment conditions

  • Analyze MAGI3 levels in conjunction with signaling pathway markers (phospho-ERK)

  • Correlate MAGI3 expression with functional readouts

When properly optimized, flow cytometry can provide quantitative data on MAGI3 expression levels across heterogeneous cell populations while simultaneously measuring activation states of associated signaling pathways.

How can I use MAGI3 antibodies for multiplexed imaging studies of protein interactions?

For advanced multiplexed imaging of MAGI3 and its interaction partners:

• Multiplex immunofluorescence techniques:

  • Sequential staining with antibody stripping between rounds

  • Tyramide signal amplification (TSA) for enhanced detection

  • Spectral unmixing to separate overlapping fluorophores

  • Multi-epitope ligand cartography (MELC) for high-parameter imaging

• Spatial analysis of protein interactions:

  • Proximity ligation assay (PLA) to visualize MAGI3 interactions with:

    • MAS receptor (to study sunitinib sensitivity mechanisms)

    • PTEN (to investigate AKT regulation)

    • Tyrosine phosphorylated proteins (to examine receptor tyrosine kinase signaling)

  • FRET-based approaches to measure direct protein interactions

• Super-resolution microscopy applications:

  • Structured illumination microscopy (SIM) for 2× resolution improvement

  • Stimulated emission depletion (STED) microscopy for nanoscale resolution

  • Single-molecule localization microscopy for precise localization of MAGI3

• Tissue-specific considerations:

  • For kidney tissues (relevant to RCC research):

    • Optimize antigen retrieval (EDTA buffer pH 9.0 often works well)

    • Use Sudan Black to reduce autofluorescence

    • Consider tissue clearing techniques for 3D imaging

• Quantification strategies:

  • Measure co-localization coefficients (Manders, Pearson's)

  • Implement machine learning algorithms for pattern recognition

  • Quantify spatial relationships between MAGI3 and other proteins

This approach can provide unprecedented insights into the spatial organization of MAGI3 signaling complexes within cells and tissues, particularly in the context of cancer progression and treatment response.

How might MAGI3 antibodies be used to develop therapeutic strategies for cancer treatment?

Emerging research suggests several potential therapeutic applications of MAGI3 antibodies:

• Diagnostic and prognostic applications:

  • Development of immunohistochemistry-based companion diagnostics to identify patients likely to benefit from sunitinib treatment

  • Creation of MAGI3-based stratification systems for clinical trial enrollment

  • Design of antibody-based assays to monitor treatment response

• Therapeutic targeting strategies:

  • Screening for drugs that mimic MAGI3-PDZ1 function to negatively regulate the MAS-ERK pathway

  • Development of biologics that can restore MAGI3 function in tumors with low expression

  • Combination therapies targeting both MAGI3-related pathways and current standard treatments

• Antibody-drug conjugate possibilities:

  • For tumors with surface expression of MAGI3 interaction partners

  • Leveraging knowledge of MAGI3 pathway biology to identify optimal drug payloads

  • Designing targeting strategies for MAS receptor or other MAGI3-interacting proteins

• Immune microenvironment considerations:

  • Investigating MAGI3's role in tumor-immune interactions

  • Exploring potential synergies between MAGI3-targeted therapies and immunotherapies

  • Using MAGI3 antibodies to study changes in tumor microenvironment during treatment

While direct therapeutic applications are still emerging, MAGI3 antibodies are currently essential tools for advancing our understanding of the molecular mechanisms that could lead to novel therapeutic approaches in renal cell carcinoma and potentially other cancers.

What are the latest findings about MAGI3 truncation and its implications for antibody-based detection methods?

Recent research on MAGI3 truncation has important implications for antibody-based detection:

• Premature polyadenylation events:

  • Studies have identified pPA (premature polyadenylation) events at cryptic intronic poly(A) signals in MAGI3

  • These events generate truncated MAGI3 variants that may have dominant-acting properties

  • Truncated forms have been detected in human breast cancer via RNA-Seq data analysis from TCGA

• Antibody epitope considerations:

  • Antibodies targeting different domains of MAGI3 may yield varying results:

    • N-terminal targeting antibodies: Will detect both full-length and truncated forms

    • C-terminal targeting antibodies: Will detect only full-length MAGI3

    • Domain-specific antibodies: May provide insights into which domains are retained in truncated forms

• Methodological recommendations:

  • Use multiple antibodies targeting different epitopes to comprehensively analyze MAGI3 status

  • Combine protein detection (antibody-based) with RNA analysis to identify truncation events

  • Consider western blotting with gradient gels to better resolve potential truncated variants

  • When interpreting IHC results, be aware that different antibodies may reveal different expression patterns

• Research implications:

  • Truncated forms may have altered functional properties compared to full-length MAGI3

  • Some cancer-related phenotypes may be driven by dominant-negative effects of truncated MAGI3

  • Understanding the balance between full-length and truncated forms may provide additional prognostic information